During the past decade, Matsuyama Red Cross Hospital conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 7 clinical trials were completed, i.e. on average, 30.4% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 6 clinical trials were completed. i.e. 46.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Matsuyama Red Cross Hospital" #1 sponsor was "Janssen Research & Development, LLC" with 7 trials, followed by "Celgene" with 5 trials sponsored, "Janssen Pharmaceutical K.K." with 2 trials sponsored, "Pfizer" with 2 trials sponsored and "W.L.Gore & Associates" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Matsuyama Red Cross Hospital" #1 collaborator was "AbbVie" with 1 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "Japan Agency for Medical Research and Development" with 1 trials as a collaborator, "Japan Lung Cancer Society" with 1 trials as a collaborator and "Ministry of Health, Labour and Welfare, Japan" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Matsuyama Red Cross Hospital" are "Multiple Myeloma" (6 trials), "Myelodysplastic Syndromes" (3 trials), "Healthy Subjects" (2 trials), "Peripheral Arterial Disease" (2 trials) and "AML Arising From Myelodysplastic Syndrome (MDS)" (1 trials). Many other conditions were trialed in "Matsuyama Red Cross Hospital" in a lesser frequency.

Most popular intervention types in "Matsuyama Red Cross Hospital" are "Drug" (21 trials), "Biological" (3 trials), "Other" (3 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Bortezomib" (6 trials), "Daratumumab" (6 trials), "Dexamethasone" (6 trials), "Placebo" (4 trials) and "Carfilzomib" (3 trials). Other intervention names were less common.

The vast majority of trials in "Matsuyama Red Cross Hospital" are 26 trials for "All" genders.

Currently, there are NaN active trials in "Matsuyama Red Cross Hospital". undefined are not yet recruiting, 7 are recruiting, 13 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Matsuyama Red Cross Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Matsuyama Red Cross Hospital, 3 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".